By Torpedo / 19th May, 2020

Radiation doses from Terbium-161 and Lutetium-177 in single tumour cells and micrometastases

Targeted radionuclide therapy (TRT) is gaining importance. For TRT to be also used as adjuvant therapy or for treating minimal residual disease, there is a need to increase the radiation dose to small tumours. The aim of this in silico study was to compare the performances of Terbium-161 (a medium-energy β− emitter with additional Auger and conversion electron emissions) and Lutetium-177 for irradiating single tumour cells and micrometastases, with various distributions of the radionuclide.